CoChat
Sign Up
Cited by 173

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions

Verma, Nagendra, Arora, Swati·2025·Pharmaceutics
DOI 10.3390/pharmaceutics17080990PMC PMC12389065
Open this paper in CoChat — free account

Abstract

Extracellular vesicle (EV)-based therapies have attracted considerable attention as a novel class of biologics with broad clinical potential. However, their clinical translation is impeded by the fragmented and rapidly evolving regulatory landscape, with significant disparities between the United States, European Union, and key Asian jurisdictions. In this review, we systematically analyze regional guidelines and strategic frameworks governing EV therapeutics, emphasizing critical hurdles in quality control, safety evaluation, and efficacy demonstration. We further explore the implications of EVs’ heterogeneity on product characterization and the emerging direct-to-consumer market for EVs and secretome preparations. Drawing on these insights, in this review, we aim to provide a roadmap for harmonizing regulatory requirements, advancing standardized analytical approaches, and fostering ongoing collaboration among regulatory authorities, industry stakeholders, and academic investigators. Such coordinated efforts are essential to safeguard patient welfare, ensure product consistency, and accelerate the responsible integration of EV-based interventions into clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/pharmaceutics17080990

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Comparative overview of the principal advantages and key challenges in exosome-based therapeutics. (Left Panel): core advantages—efficient barrier crossing, high biocompatibility and low immunogenicity, versatile cargo loading, targeted delivery, and improved stability. (Right Panel): main hurdles—regulatory ambiguity, mechanistic gaps, scale-up and purification constraints, quality control issues, and batch heterogeneity.
Figure 1 Comparative overview of the principal advantages and key challenges in exosome-based therapeutics. (Left Panel): core advantages—efficient barrier crossing, high biocompatibility and low immunogenicity, versatile cargo loading, targeted delivery, and improved stability. (Right Panel): main hurdles—regulatory ambiguity, mechanistic gaps, scale-up and purification constraints, quality control issues, and batch heterogeneity.CC BY · PubMed Central
Figure 2 The proportion of EV-based clinical trials registered in the WHO ICTRP by regulatory jurisdiction. China-NMPA accounts for 61% of total registrations, followed by the U.S.A.’s FDA (17%), Japan’s PMDA (7%), India’s CDSCO (4%), South Korea’s MFDS, Australia’s TGA, and the United Kingdom (3% each), with smaller shares from the EU’s EMA (CTIS) (1%), Taiwan’s TFDA (1%), and Switzerland’s Swissmedic (<1%).
Figure 2 The proportion of EV-based clinical trials registered in the WHO ICTRP by regulatory jurisdiction. China-NMPA accounts for 61% of total registrations, followed by the U.S.A.’s FDA (17%), Japan’s PMDA (7%), India’s CDSCO (4%), South Korea’s MFDS, Australia’s TGA, and the United Kingdom (3% each), with smaller shares from the EU’s EMA (CTIS) (1%), Taiwan’s TFDA (1%), and Switzerland’s Swissmedic (<1%).CC BY · PubMed Central
Figure 3 Global regulatory ecosystem for EV-based therapeutics. Centralized ICH-driven harmonization through ISEV/MISEV guidelines informs regional frameworks, guiding content characterization and safety assessment. Divergent country-specific pathways—USA (FDA), EU (EMA), South Korea (MFDS), Japan (PMDA), India (CDSCO/ICMR), Taiwan (TFDA), China (NMPA), UK (MHRA), Switzerland (Swissmedic)—are mapped alongside regulatory classifications (e.g., biologics, ATMPs) and approval processes. This schematic underscores the complexity and the need for unified standards.
Figure 3 Global regulatory ecosystem for EV-based therapeutics. Centralized ICH-driven harmonization through ISEV/MISEV guidelines informs regional frameworks, guiding content characterization and safety assessment. Divergent country-specific pathways—USA (FDA), EU (EMA), South Korea (MFDS), Japan (PMDA), India (CDSCO/ICMR), Taiwan (TFDA), China (NMPA), UK (MHRA), Switzerland (Swissmedic)—are mapped alongside regulatory classifications (e.g., biologics, ATMPs) and approval processes. This schematic underscores the complexity and the need for unified standards.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 75

  1. Lee, K.W.A., Chan, L.K.W., Hung, L.C., Lam, P.K.W., Park, Y., and Yi, K.H. (2024). Clinical Applications of Exosomes: A Critical Review. Int. J. Mol. Sci., 25. · DOI · Paper page
  2. Cheng, 2024, Stem cell exosomes: New hope for recovery from diabetic brain hemorrhage, World J. Diabetes, 15, 2264, 10.4239/wjd.v15.i11.2264 · DOI
  3. Zhou, 2020, Application of Exosomes as Liquid Biopsy in Clinical Diagnosis, Signal Transduct. Target. Ther., 5, 144, 10.1038/s41392-020-00258-9 · DOI · Paper page
  4. Rezaie, 2022, A Review on Exosomes Application in Clinical Trials: Perspective, Questions, and Challenges, Cell Commun. Signal, 20, 145, 10.1186/s12964-022-00959-4 · DOI
  5. Chen, Y.F., Luh, F., Ho, Y.S., and Yen, Y. (2024). Exosomes: A review of biologic function, diagnostic and targeted therapy applications, and clinical trials. J. Biomed. Sci., 31. · DOI
  6. Choudhery, M.S., Arif, T., Mahmood, R., and Harris, D.T. (2024). Stem Cell-Based Acellular Therapy: Insight into Biogenesis, Bioengineering and Therapeutic Applications of Exosomes. Biomolecules, 14. · DOI
  7. Newton, 2017, Stem cell-derived exosomes: A novel vector for tissue repair and diabetic therapy, J. Mol. Endocrinol., 59, R155, 10.1530/JME-17-0080 · DOI
  8. Chu, C.-H., Lee, R.P., Wu, W.T., Chen, I.-H., Yeh, K.T., and Wang, C.C. (2024). Advancing Osteoarthritis Treatment: The Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes and Biomaterial Integration. Biomedicines, 12. · DOI
  9. Kar, 2023, Exosome-Based Smart Drug Delivery Tool for Cancer Theranostics, ACS Biomater. Sci. Eng., 9, 577, 10.1021/acsbiomaterials.2c01329 · DOI
  10. Yong, 2019, Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy, Nat. Commun., 10, 3838, 10.1038/s41467-019-11718-4 · DOI · Paper page
  11. Sousa, P., Lopes, B., Sousa, A.C., Moreira, A., Coelho, A., Alvites, R., Alves, N., Geuna, S., and Mauricio, A.C. (2023). Advancements and Insights in Exosome-Based Therapies for Wound Healing: A Comprehensive Systematic Review (2018–June 2023). Biomedicines, 11. · DOI
  12. Xu, 2020, Exosome-based immunotherapy: A promising approach for cancer treatment, Mol. Cancer, 19, 160, 10.1186/s12943-020-01278-3 · DOI · Paper page
  13. Fu, 2019, CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity, Nat. Commun., 10, 4355, 10.1038/s41467-019-12321-3 · DOI
  14. Wang, 2024, Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes, Clin. Transl. Sci., 17, e13904, 10.1111/cts.13904 · DOI
  15. Chen, 2020, Exosomes in clinical trial and their production in compliance with good manufacturing practice, Tzu Chi Med. J., 32, 113, 10.4236/cm.2020.113007 · DOI
  16. Wiest, E.F., and Zubair, A.C. (2025). Generation of Current Good Manufacturing Practices-Grade Mesenchymal Stromal Cell-Derived Extracellular Vesicles Using Automated Bioreactors. Biology, 14. · DOI
  17. Nolan, K.J. (2010). Enforcement of Current Good Manufacturing Practices. Pharmaceutical Sciences Encyclopedia, John Wiley & Sons, Inc. · DOI
  18. Harris, J.R. (2008). Good Manufacturing Practices (GMP) and Related FDA Guidelines. Pharmaceutical Manufacturing Handbook, John Wiley & Sons, Inc. · DOI
  19. Chu, 2022, Nebulization Therapy with Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for COVID-19 Pneumonia, Stem Cell Rev. Rep., 18, 2152, 10.1007/s12015-022-10398-w · DOI
  20. Raghav, A., Khan, Z.A., Upadhayay, V.K., Tripathi, P., Gautam, K.A., Mishra, B.K., Ahmad, J., and Jeong, G.B. (2021). Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients. Cells, 10. · DOI
  21. Antounians, 2021, The Role of Exosomes in the Treatment, Prevention, Diagnosis, and Pathogenesis of COVID-19, Eur. J. Pediatr. Surg., 31, 326, 10.1055/s-0041-1731294 · DOI
  22. Park, H.S., Cetin, E., Siblini, H., Seok, J., Alkelani, H., Alkhrait, S., Liakath Ali, F., Mousaei Ghasroldasht, M., Beckman, A., and Al-Hendy, A. (2023). Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles to Treat PCOS. Int. J. Mol. Sci., 24. · DOI
  23. Lee, B.C., Kang, I., and Yu, K.R. (2021). Therapeutic Features and Updated Clinical Trials of Mesenchymal Stem Cell (MSC)-Derived Exosomes. J. Clin. Med., 10. · DOI
  24. Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., and Liu, J. (2022). Recent advances in exosome-mediated nucleic acid delivery for cancer therapy. J. Nanobiotechnology, 20. · DOI · Paper page
  25. Lu, Y., Huang, W., Li, M., and Zheng, A. (2023). Exosome-Based Carrier for RNA Delivery: Progress and Challenges. Pharmaceutics, 15. · DOI
  26. Chew, 2025, Exosomes as promising frontier approaches in future cancer therapy, World J. Gastrointest. Oncol., 17, 100713, 10.4251/wjgo.v17.i1.100713 · DOI
  27. Sonar, 2024, Clinical trial status of exosomes-based cancer theranostics, Clin. Transl. Discov., 4, e327, 10.1002/ctd2.327 · DOI
  28. Li, 2021, Therapeutic application of exosomes in ischaemic stroke, Stroke Vasc. Neurol., 6, 483, 10.1136/svn-2020-000419 · DOI
  29. Jiang, L., Chen, W., Ye, J., and Wang, Y. (2022). Potential Role of Exosomes in Ischemic Stroke Treatment. Biomolecules, 12. · DOI
  30. Baghaei, 2019, Exosomes as a novel cell-free therapeutic approach in gastrointestinal diseases, J. Cell. Physiol., 234, 9910, 10.1002/jcp.27934 · DOI
  31. Sharma, A., Yadav, A., Nandy, A., and Ghatak, S. (2024). Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine. Pharmaceutics, 16. · DOI
  32. Li, X., Corbett, A.L., Taatizadeh, E., Tasnim, N., Little, J.P., Garnis, C., Daugaard, M., Guns, E., Hoorfar, M., and Li, I.T.S. (2019). Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy. APL Bioeng., 3. · DOI
  33. Ren, 2019, Exosomes in perspective: A potential surrogate for stem cell therapy, Odontology, 107, 271, 10.1007/s10266-018-0395-9 · DOI
  34. Ludwig, N., Whiteside, T.L., and Reichert, T.E. (2019). Challenges in Exosome Isolation and Analysis in Health and Disease. Int. J. Mol. Sci., 20. · DOI
  35. Martinez-Espinosa, I., Serrato, J.A., and Ortiz-Quintero, B. (2023). The Role of Exosome-Derived microRNA on Lung Cancer Metastasis Progression. Biomolecules, 13. · DOI
  36. Shaun, 2020, Exosomes as therapeutics and drug delivery vehicles: Global regulatory perspectives, Cell Gene Ther. Insights, 6, 1561, 10.18609/cgti.2020.172 · DOI
  37. Pawanbir, 2010, Exploratory assessment of the current EU regulatory framework for development of advanced therapies, J. Commer. Biotechnol., 16, 331, 10.1057/jcb.2010.18 · DOI
  38. Daisuke, 2015, Regulatory Frameworks for Gene and Cell Therapies in Japan, Adv. Exp. Med. Biol., 871, 147, 10.1007/978-3-319-18618-4_8 · DOI
  39. Lener, 2015, Applying extracellular vesicles based therapeutics in clinical trials—An ISEV position paper, J. Extracell. Vesicles, 4, 30087, 10.3402/jev.v4.30087 · DOI · Paper page
  40. Batrakova, 2016, Development and regulation of exosome-based therapy products, Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 8, 744, 10.1002/wnan.1395 · DOI
  41. Ma, 2025, Engineering therapeutical extracellular vesicles for clinical translation, Trends Biotechnol., 43, 61, 10.1016/j.tibtech.2024.08.007 · DOI
  42. Stawarska, A., Bamburowicz-Klimkowska, M., Rundén-Pran, E., Dusinska, M., Cimpan, M.R., Rios-Mondragon, I., and Grudzinski, I.P. (2024). Extracellular Vesicles as Next-Generation Diagnostics and Advanced Therapy Medicinal Products. Int. J. Mol. Sci., 25. · DOI
  43. Fujita, 2024, The urgent need for clear and concise regulations on exosome-based interventions, Stem Cell Rep., 19, 1517, 10.1016/j.stemcr.2024.09.008 · DOI
  44. Lysaght, 2017, Accelerating regenerative medicine: The Japanese experiment in ethics and regulation, Regen. Med., 12, 657, 10.2217/rme-2017-0038 · DOI
  45. Fujita, 2016, Regenerative medicine legislation in Japan for fast provision of cell therapy products, Clin. Pharmacol. Ther., 99, 26, 10.1002/cpt.279 · DOI
  46. Tsuchiya, 2022, Basic points to consider regarding the preparation of extracellular vesicles and their clinical applications in Japan, Regen. Ther., 21, 19, 10.1016/j.reth.2022.05.003 · DOI
  47. Chao, 2023, Update on Regulation of Regenerative Medicine in Taiwan, Adv. Exp. Med. Biol., 1430, 211, 10.1007/978-3-031-34567-8_12 · DOI
  48. Chen, 2017, Cell Therapy Regulation in Taiwan, Cell Transplant., 26, 483, 10.3727/096368916X693293 · DOI
  49. S, S.K., Joga, R., Srivastava, S., Nagpal, K., Dhamija, I., Grover, P., and Kumar, S. (2024). Regulatory landscape and challenges in CAR-T cell therapy development in the US, EU, Japan, and India. Eur. J. Pharm. Biopharm., 201. · DOI
  50. Thakur, A., and Rai, D. (2024). Global requirements for manufacturing and validation of clinical grade extracellular vesicles. J. Liq. Biopsy, 6. · DOI
  51. Asadpour, 2023, Uncovering the gray zone: Mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes, Stem Cell Res. Ther., 14, 111, 10.1186/s13287-023-03335-2 · DOI
  52. Bukovac, 2023, The Regulation of Cell Therapy and Gene Therapy Products in Switzerland, Adv. Exp. Med. Biol., 1430, 41, 10.1007/978-3-031-34567-8_3 · DOI
  53. Queen, 2025, Exosomes for Treating Hair Loss: A Review of Clinical Studies, Dermatol. Surg., 51, 409, 10.1097/DSS.0000000000004480 · DOI
  54. Ahn, 2022, Manufacturing Therapeutic Exosomes: From Bench to Industry, Mol. Cells, 45, 284, 10.14348/molcells.2022.2033 · DOI
  55. Maitra, 2024, Targeted therapies for HPV-associated cervical cancer: Harnessing the potential of exosome-based chipsets in combating leukemia and HPV-mediated cervical cancer, J. Med. Virol., 96, e29596, 10.1002/jmv.29596 · DOI
  56. Willis, G.R., Kourembanas, S., and Mitsialis, S.A. (2017). Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency. Front. Cardiovasc. Med., 4. · DOI
  57. Singh, 2021, Separation of distinct exosome subpopulations: Isolation and characterization approaches and their associated challenges, Analyst, 146, 3731, 10.1039/D1AN00024A · DOI
  58. Wang, Z., Wang, Q., Qin, F., and Chen, J. (2024). Exosomes: A promising avenue for cancer diagnosis beyond treatment. Front. Cell Dev. Biol., 12. · DOI · Paper page
  59. Kibria, 2018, Exosomes as a Drug Delivery System in Cancer Therapy: Potential and Challenges, Mol. Pharm., 15, 3625, 10.1021/acs.molpharmaceut.8b00277 · DOI
  60. Zhang, 2019, Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip, Nat. Biomed. Eng., 3, 438, 10.1038/s41551-019-0356-9 · DOI
  61. Gurung, 2021, The exosome journey: From biogenesis to uptake and intracellular signalling, Cell Commun. Signal, 19, 47, 10.1186/s12964-021-00730-1 · DOI
  62. Pharmaceuticals and Medical Devices Agency (2025, July 24). Clinical Trial Notification (CTN)—Process and Requirements. Available online: https://www.pmda.go.jp/english/review-services/regulatory-info/0016.html.
  63. Milne, 2016, Prospects for Harmonizing Regulatory Science Programs in Europe, Japan, and the United States to Advance Regenerative Medicine, Ther. Innov. Regul. Sci., 50, 724, 10.1177/2168479016650716 · DOI
  64. Ndomondo-Sigonda, M., Miot, J., Naidoo, S., Masota, N., Ng’andu, B., Ngum, N., and Kaale, E. (2021). Harmonization of Medical Products Regulation: A Key Factor for Improving Regulatory Capacity in the East African Community. BMC Public Heal., 21. · DOI
  65. Mullin, 2019, International Conference on Harmonization: Recent Reforms as a Driver of Global Regulatory Harmonization and Innovation in Medical Products, Clin. Pharmacol. Ther., 105, 926, 10.1002/cpt.1289 · DOI
  66. Rosemann, 2016, The pluralization of the international: Resistance and alter-standardization in regenerative stem cell medicine, Soc. Stud. Sci., 46, 112, 10.1177/0306312715619783 · DOI
  67. Kleiderman, 2018, Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials, Stem Cell Res. Ther., 9, 307, 10.1186/s13287-018-1055-2 · DOI · Paper page
  68. Ghaffari, K., Moradi-Hasanabad, A., Sobhani-Nasab, A., Javaheri, J., and Ghasemi, A. (2023). Application of cell-derived exosomes in the hematological malignancies therapy. Front. Pharmacol., 14. · DOI
  69. Li, 2025, Exosomes: Innovative biomarkers leading the charge in non-invasive cancer diagnostics, Theranostics, 15, 5277, 10.7150/thno.113650 · DOI
  70. Youssef, E., Palmer, D., Fletcher, B., and Vaughn, R. (2025). Exosomes in Precision Oncology and Beyond: From Bench to Bedside in Diagnostics and Therapeutics. Cancers, 17. · DOI
  71. Das, 2019, Exosome as a Novel Shuttle for Delivery of Therapeutics across Biological Barriers, Mol. Pharm., 16, 24, 10.1021/acs.molpharmaceut.8b00901 · DOI
  72. Sitbon, 2024, Mesenchymal stromal cell-derived extracellular vesicles therapy openings new translational challenges in immunomodulating acute liver inflammation, J. Transl. Med., 22, 480, 10.1186/s12967-024-05282-9 · DOI
  73. Jaalouk, D., Prasai, A., Goldberg, D.J., and Yoo, J.Y. (2024). Regulatory Aspects of Regenerative Medicine in the United States and Abroad. Dermatol. Rev., 5. · DOI
  74. Jafari, N., Zolfi Gol, A., Shahabi Rabori, V., and Saberiyan, M. (2025). Exploring the role of exosomal and non-exosomal non-coding RNAs in Kawasaki disease: Implications for diagnosis and therapeutic strategies against coronary artery aneurysms. Biochem. Biophys. Rep., 42. · DOI
  75. Vakil, D., Doshi, R., McKinnirey, F., and Sidhu, K. (2023). Stem Cell-Derived Exosomes as New Horizon for Cell-Free Therapeutic Development: Current Status and Prospects, IntechOpen. · DOI

Cited by

Sorted by citations

See all 173

Metadata

Authors
Verma, N., & Arora, S.
Venue
Pharmaceutics
Publisher
MDPI AG
Published
2025-07-30
Volume
17
Issue
8
Pages
990
ISSN
1999-4923
DOI
10.3390/pharmaceutics17080990
PMC
PMC12389065
Cited by
173
References
3
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review